Major Japanese Pharmaceutical Companies Foresee Increase In Revenue And Profits
This article was originally published in PharmAsia News
Several Japanese pharma companies are predicting a rise in profits. Although Daiichi Sankyo spun off its non-drug business, it sees an increase in revenue and profits in its drug business. Astellas plans on expanding its domestic and overseas market share for its global products, such as immunosuppressant drugs and an overactive bladder treatment, and an increase in profit as a result of lower R&D expenses. Eisai is focusing on accelerating development of its Alzheimer's and anti-ulcerogenic drugs. Taisho revised its estimate upward because of a positive showing for its new products sector. Along with pipeline activities, these companies are improving cost ratios to gear up for overseas expanions in Europe and North America. (Click for more-Japanese language
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.